Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy.
Pharmacologic inhibition of indoleamine 2,3-dioxygenase (IDO) activity during murine pregnancy results in maternal T-cell-mediated rejection of allogeneic but not syngeneic conceptuses. Increased risk of allogeneic pregnancy failure induced by exposure to IDO inhibitor is strongly correlated with maternal C3 deposition at the maternal-fetal interface. Here we review evidence that cells expressing IDO contribute to immunosuppression by inhibiting T-cell responses to tumor antigens and tissue allografts, as well as fetal tissues.
Mellor
Andrew L
AL
Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA. amellor@mail.mcg.edu
Chandler
Phillip
P
Lee
Geon Kook
GK
Johnson
Theodore
T
Keskin
Derin B
DB
Lee
Jeffrey
J
Munn
David H
DH
D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007249:Inflammation / Q000201:enzymology / Q000276:immunology; D008431:Maternal-Fetal Exchange / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D009369:Neoplasms / Q000201:enzymology / Q000276:immunology; D011247:Pregnancy; D013601:T-Lymphocytes / Q000276:immunology; D014181:Transplantation Immunology; D014366:Tryptophan Oxygenase / Q000037:antagonists & inhibitors / Q000276:immunology*
D004791:Enzyme Inhibitors; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D014366:Tryptophan Oxygenase